Evidence map›Paper›PMID 39724464›Full record

ArticleCancer reports (Hoboken, N.J.)2024

Efficacy of Combined Encorafenib and Binimetinib Treatment for Erdheim-Chester Disease Harboring Concurrent BRAF

Yuto Hibino, Rika Sakai, Hiroyuki Takahashi, Takaaki Takeda, Natsuki Hirose, Mayumi Tokunaga, Kota Washimi, Tomoyuki Yokose, Rika Kasajima, Yukihiko Hiroshima and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuto HibinoDepartment of Hematology and Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.ORCID 0009-0006-3210-9491
Rika SakaiDepartment of Hematology and Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Hiroyuki TakahashiDepartment of Hematology and Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.ORCID 0000-0001-5188-9063
Takaaki TakedaDepartment of Hematology and Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Natsuki HiroseDepartment of Hematology and Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Mayumi TokunagaDepartment of Hematology and Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Kota WashimiDepartment of Pathology, Kanagawa Cancer Center, Yokohama, Japan.ORCID 0000-0001-6353-776X
Tomoyuki YokoseDepartment of Pathology, Kanagawa Cancer Center, Yokohama, Japan.
Rika KasajimaCenter for Cancer Genome Medicine, Kanagawa Cancer Center, Yokohama, Japan.
Yukihiko HiroshimaCenter for Cancer Genome Medicine, Kanagawa Cancer Center, Yokohama, Japan.
Yohei MiyagiKanagawa Cancer Center Research Institute, Yokohama, Japan.
Hideaki NakajimaDepartment of Hematology and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundErdheim-Chester disease (ECD) is a rare form of non-Langerhans cell histiocytosis with diverse clinical manifestations, often associated with mutations in the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway. BRAF and KRAS mutations, which are driver mutations of oncogenes, participate in the same signaling pathway (MAPK/ERK pathway) and are usually mutually exclusive. We report a case of ECD with concurrent BRAF CASE: A 70-year-old man was referred to our hospital with a mesenteric nodal lesion on computed tomography scan. The patient experienced symptoms consistent with ECD, including central diabetes insipidus. Biopsy revealed histiocytes positive for CD68 and CD163, negative for S100, CD1a, and CD21. Liquid-based comprehensive genomic profiling and tissue-based cancer gene panel test identified BRAF

conclusionThis case represents a unique presentation of ECD with concurrent BRAF

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBenzimidazolesCarbamatesErdheim-Chester DiseaseMutationProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)SulfonamidesAgedHumansMaleTreatment OutcomeBenzimidazolesbinimetinibBRAF protein, humanCarbamatesencorafenibKRAS protein, humanProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)SulfonamidesBRAF inhibitorErdheim–Chester diseasegenomic profilinghistiocytosisMEK inhibitormolecular‐targeted therapy

Identifiers

PMID39724464
PMCPMC11670472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.